<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37591618</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020-2021.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003250</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003250</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="METHODS">This retrospective cohort study identified adults with SLE in the Merative&#x2122; MarketScan<sup>&#xae;</sup> Databases. Patients were continuously enrolled the year before 1 April 2020 (baseline) and had a COVID-19 diagnosis between 1 April 2020 and the earliest of death, enrolment end or 31 December 2021. Severe COVID-19 was defined as hospitalisation with a COVID-19 diagnosis. Demographics on 1 April 2020, baseline comorbidities, corticosteroid use &#x2264;30&#x2009;days before COVID-19 diagnosis and other SLE medication use &#x2264;6 months before COVID-19 diagnosis were assessed. Vaccination was identified by claims for a COVID-19 vaccine or vaccine administration. Backward stepwise logistic regression estimated odds of progression to severe COVID-19 associated with patient characteristics and vaccination.</AbstractText><AbstractText Label="RESULTS">Among 2890 patients with SLE with COVID-19, 500 (16.4%) had a COVID-19-related hospitalisation. Significant risk factors for progression to severe COVID-19 included rituximab (OR (95%&#x2009;CI) 2.92 (1.67 to 5.12)), renal failure (2.15 (95% CI 1.56 to 2.97)), Medicaid (vs Commercial; 2.01 (95% CI 1.58 to 2.57)), complicated hypertension (1.96 (95% CI 1.38 to 2.77)) and time of infection, among others. Vaccination had a significant protective effect (0.68(95% CI 0.54 to 0.87)) among all patients with SLE with COVID-19, but the effect was not significant among those with prior use of belimumab, rituximab or corticosteroids.</AbstractText><AbstractText Label="CONCLUSIONS">Certain chronic comorbidities and SLE medications increase the odds of progression to severe COVID-19 among patients with SLE, but vaccination confers significant protection. Vaccine effectiveness may be attenuated by SLE treatments. Protective measures such as pre-exposure prophylaxis and booster vaccines should be encouraged among patients with SLE.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8773-7739</Identifier><AffiliationInfo><Affiliation>Rheumatic &amp; Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atefi</LastName><ForeName>Gelareh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>US Medical, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Kristin A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-0987-1745</Identifier><AffiliationInfo><Affiliation>Real World Data Research and Analytics, Merative, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moynihan</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real World Data Research and Analytics, Merative, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Liisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Real World Data Research and Analytics, Merative, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Sze-Jung</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>US Medical, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA sandrasze-jung.wu@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological Therapy</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immune System Diseases</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Competing interests: S-JW and GA are employed by AstraZeneca. KAE, MM and LP are employed by Merative which received funding from AstraZeneca to conduct this study. CC is a paid consultant of AstraZeneca, as well as Eli Lilly, Pfizer and Sanofi. Results of this research have been presented in part at the 2022 American College of Rheumatology annual meeting (ACR Convergence) in Philadelphia, Pennsylvania, USA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>17</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37591618</ArticleId><ArticleId IdType="pmc">PMC10441046</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003250</ArticleId><ArticleId IdType="pii">rmdopen-2023-003250</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention . COVID data Tracker. Available: https://covid.cdc.gov/covid-data-tracker/#datatracker-home [Accessed 06 Oct 2022].</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . Estimated COVID-19 burden. Available: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html#est-infections [Accessed 06 Oct 2022].</Citation></Reference><Reference><Citation>Marozoff S, Lu N, Loree JM, et al. . Severe COVID-19 outcomes among patients with autoimmune rheumatic diseases or transplantation: a population-based matched cohort study. BMJ Open 2022;12:e062404. 10.1136/bmjopen-2022-062404</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062404</ArticleId></ArticleIdList></Reference><Reference><Citation>Avouac J, Drumez E, Hachulla E, et al. . COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with Rituximab: a cohort study. Lancet Rheumatol 2021;3:e419&#x2013;26. 10.1016/S2665-9913(21)00059-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00059-X</ArticleId><ArticleId IdType="pmc">PMC7993930</ArticleId><ArticleId IdType="pubmed">33786454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoglio IM, Valim JM de L, Daffre D, et al. . Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study of 252,119 patients. ACR Open Rheumatol 2021;3:804&#x2013;11. 10.1002/acr2.11329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11329</ArticleId><ArticleId IdType="pmc">PMC8593786</ArticleId><ArticleId IdType="pubmed">34423922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported Registry. Ann Rheum Dis 2020;79:859&#x2013;66. 10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Izadi Z, et al. . Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis 2022;81:970&#x2013;8. 10.1136/annrheumdis-2021-221636</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>Radwan NM, Mahmoud NE, Alfaifi AH, et al. . Comorbidities and severity of Coronavirus disease 2019 patients. Saudi Med J 2020;41:1165&#x2013;74. 10.15537/smj.2020.11.25454</Citation><ArticleIdList><ArticleId IdType="doi">10.15537/smj.2020.11.25454</ArticleId><ArticleId IdType="pmc">PMC7804237</ArticleId><ArticleId IdType="pubmed">33130835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Yang Q, Chi J, et al. . Comorbidities and the risk of severe or fatal outcomes associated with Coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020;99:47&#x2013;56. 10.1016/j.ijid.2020.07.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.07.029</ArticleId><ArticleId IdType="pmc">PMC7381888</ArticleId><ArticleId IdType="pubmed">32721533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Ferr&#xe9; VM, Goulenok T, et al. . Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2022;81:1194&#x2013;6. 10.1136/annrheumdis-2022-222498</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222498</ArticleId><ArticleId IdType="pubmed">35396228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ARYB, Wong SY, Chai LYA, et al. . Efficacy of COVID-19 vaccines in immunocompromised patients: systemic review and meta-analysis. BMJ 2022;376:e068632. 10.1136/bmj-2021-068632</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zheng Q, Madhira V, et al. . Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med 2022;182:153&#x2013;62. 10.1001/jamainternmed.2021.7024</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.7024</ArticleId><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammitzb&#xf8;ll C, Bartels LE, B&#xf8;gh Andersen J, et al. . Impaired antibody response to the BNT162b2 messenger RNA Coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 2021;3:622&#x2013;8. 10.1002/acr2.11299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11299</ArticleId><ArticleId IdType="pmc">PMC8426741</ArticleId><ArticleId IdType="pubmed">34273260</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Kim MY, Samanovic M, et al. . Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol 2022;74:284&#x2013;94. 10.1002/art.41937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pmc">PMC8426963</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C, Ursini F, Gragnani L, et al. . Impaired Immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. high prevalence of non-response in different patients' subgroups. J Autoimmun 2021;125:102744. 10.1016/j.jaut.2021.102744</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102744</ArticleId><ArticleId IdType="pmc">PMC8577991</ArticleId><ArticleId IdType="pubmed">34781162</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese CM, Kirchner E, Husni EM, et al. . Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell depleting therapy: a retrospective cohort analysis. Arthritis Rheumatol 2022;74:1906&#x2013;15. 10.1002/art.42287</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42287</ArticleId><ArticleId IdType="pmc">PMC9349969</ArticleId><ArticleId IdType="pubmed">35791921</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M, et al. . BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis 2022;81:575&#x2013;83. 10.1136/annrheumdis-2021-221097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pmc">PMC8494536</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore BJ, White S, Washington R, et al. . Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser comorbidity index. Med Care 2017;55:698&#x2013;705. 10.1097/MLR.0000000000000735</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000735</ArticleId><ArticleId IdType="pubmed">28498196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey-Re&#xf1;ones C, Martinez-Torres S, Mart&#xed;n-Luj&#xe1;n FM, et al. . Type 2 diabetes mellitus and COVID-19: a narrative review. Biomedicines 2022;10:2089. 10.3390/biomedicines10092089</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092089</ArticleId><ArticleId IdType="pmc">PMC9495673</ArticleId><ArticleId IdType="pubmed">36140191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Gasparyan AY, Zimba O, et al. . Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses. Clin Rheumatol 2022;41:3897&#x2013;913. 10.1007/s10067-022-06365-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06365-y</ArticleId><ArticleId IdType="pmc">PMC9458477</ArticleId><ArticleId IdType="pubmed">36076125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger JE, Driver M, Joung S, et al. . Hypertension and excess risk for severe COVID-19 illness despite booster vaccination. Hypertension 2022;79:e132&#x2013;4. 10.1161/HYPERTENSIONAHA.122.19694</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.122.19694</ArticleId><ArticleId IdType="pmc">PMC9444256</ArticleId><ArticleId IdType="pubmed">35862106</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawadogo W, Tsegaye M, Gizaw A, et al. . Overweight and obesity as risk factors for COVID-19-associated hospitalizations and death: a systematic review and meta-analysis. BMJ Nutr Prev Health 2022;5:10&#x2013;8. 10.1136/bmjnph-2021-000375</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjnph-2021-000375</ArticleId><ArticleId IdType="pmc">PMC8783972</ArticleId><ArticleId IdType="pubmed">35814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancarevic I, Nassar M, Daoud A, et al. . Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: a systematic review and meta-analysis. World J Virol 2022;11:352&#x2013;61. 10.5501/wjv.v11.i5.352</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i5.352</ArticleId><ArticleId IdType="pmc">PMC9523330</ArticleId><ArticleId IdType="pubmed">36188740</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Malik P, Patel N, et al. . Kidney disease and COVID-19 diseae severity - systematic review and meta-analysis. Clin Exp Med 2022;22:125&#x2013;35. 10.1007/s10238-021-00715-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00715-x</ArticleId><ArticleId IdType="pmc">PMC8063780</ArticleId><ArticleId IdType="pubmed">33891214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Masson M, Kim MY, et al. . Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol 2020;72:1971&#x2013;80. 10.1002/art.41450</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41450</ArticleId><ArticleId IdType="pmc">PMC7941257</ArticleId><ArticleId IdType="pubmed">32715660</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SM, Skendelas JP, Macdonald E, et al. . On-admission anemia predicts mortality in COVID-19 patients: a single center, retrospective cohort study. Am J Emerg Med 2021;48:140&#x2013;7. 10.1016/j.ajem.2021.03.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2021.03.083</ArticleId><ArticleId IdType="pmc">PMC8007204</ArticleId><ArticleId IdType="pubmed">33895645</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, Xu J, Chen W, et al. . Anemia is associated with severe illness in COVID-19: a retrospective cohort study. J Med Virol 2021;93:1478&#x2013;88. 10.1002/jmv.26444</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26444</ArticleId><ArticleId IdType="pmc">PMC7461220</ArticleId><ArticleId IdType="pubmed">32813298</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D, et al. . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330&#x2013;8. 10.1136/annrheumdis-2021-220647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId><ArticleId IdType="pubmed">34127481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki EFN, Borba EF, Pasoto SG, et al. . Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2022;74:562&#x2013;71. 10.1002/acr.24824</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24824</ArticleId><ArticleId IdType="pmc">PMC9011410</ArticleId><ArticleId IdType="pubmed">34806342</ArticleId></ArticleIdList></Reference><Reference><Citation>Boedecker-Lips SC, Cla&#xdf;en P, Kraus D, et al. . Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus. Rheumatology 2023;62:e34&#x2013;5. 10.1093/rheumatology/keac459</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac459</ArticleId><ArticleId IdType="pmc">PMC9384795</ArticleId><ArticleId IdType="pubmed">35972412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavoni I, Olivetta E, Natalucci F, et al. . Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with belimumab. Lupus 2023;32:394&#x2013;400. 10.1177/09612033221151012</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221151012</ArticleId><ArticleId IdType="pmc">PMC9833998</ArticleId><ArticleId IdType="pubmed">36607313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv A, Heshin-Bekenstein M, Haviv R, et al. . Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases. Rheumatology 2023;62:SI145&#x2013;51. 10.1093/rheumatology/keac408</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac408</ArticleId><ArticleId IdType="pmc">PMC9384675</ArticleId><ArticleId IdType="pubmed">35920789</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A, Engel AJ, Banbury B, et al. . Breathrough SARS-CoV-2 infections, morbidity, and Seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatol 2022;4:e582&#x2013;5. 10.1016/S2665-9913(22)00190-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00190-4</ArticleId><ArticleId IdType="pmc">PMC9275793</ArticleId><ArticleId IdType="pubmed">35856060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>